Fierce Pharma
SEPTEMBER 1, 2023
After months of legal wrangling, Amgen is free to go forward with its $27.8 billion buyout of Horizon Therapeutics. | Friday, the U.S. Federal Trade Commission (FTC) said it reached a proposed consent order with Amgen to address “the potential competitive harm” that could result from the merger deal. Now, Amgen is free to go forward with its $28 billion buyout.
MedCity News
SEPTEMBER 1, 2023
The fusion of clinical and engagement data can revolutionize the way we understand and treat patients. By optimizing data collection and synthesis, securely sharing data, and ensuring equitable access, we can make significant strides towards delivering more personalized, effective, and patient-centered care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 1, 2023
Approved two summers ago for chronic kidney disease (CKD) associated with type 2 diabetes, Bayer’s Kerendia (finerenone) isn’t off to the flying start expected of a potential blockbuster. | Bayer plans three new trials to assess its potential blockbuster medicine Kerendia in heart failure. The drug was first approved 2 years ago in CKD associated with diabetes.
MedCity News
SEPTEMBER 1, 2023
As the value-based care market gets more crowded, startups in this space will have to nail down the fundamentals in order to attract capital from investors, healthcare business expert Paul Campbell said during a virtual conference. He encouraged startups to be crystal clear about what their value proposition is for three main stakeholders — patients, providers and payers.
Fierce Pharma
SEPTEMBER 1, 2023
After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa. | After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa.
MedCity News
SEPTEMBER 1, 2023
Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 1, 2023
Through a new partnership, Bicycle Health providers can prescribe patients buprenorphine extended release injections (otherwise known as Sublocade), which can be administered by a pharmacist at an Albertsons pharmacy.
PharmaTimes
SEPTEMBER 1, 2023
The AI platform and expertise will be combined to discover novel targets for haematological cancers - News - PharmaTimes
PharmaVoice
SEPTEMBER 1, 2023
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.
Pharmaceutical Technology
SEPTEMBER 1, 2023
Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
SEPTEMBER 1, 2023
The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. Global mRNA-based oncology therapy market At present, the pharmaceutical industry is still awaiting the first regulatory approval of an mRNA-based oncology therapy. mRNA stability and delivery specificity are two of the main obstacles hindering pr
Pharmaceutical Technology
SEPTEMBER 1, 2023
Otsuka Pharmaceutical has signed a definitive arrangement agreement to acquire Mindset Pharma, in an all-cash deal worth C$80m ($59.1m).
PharmaTimes
SEPTEMBER 1, 2023
Partnership will discover and develop novel antibodies for a range of autoimmune diseases - News - PharmaTimes
Pharmaceutical Technology
SEPTEMBER 1, 2023
As per GlobalData, AbbVie has remained the Crohn’s disease market leader over the last five years, with Humira sales of $2.7bn in 2022 in 8MM.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
European Pharmaceutical Review
SEPTEMBER 1, 2023
Roche’s Alecensa ® (alectinib) is the first anaplastic lymphoma kinase (ALK) inhibitor to demonstrate a reduction in the risk of disease recurrence or death for patients with early-stage ALK-positive non-small cell lung cancer (NSCLC) in a Phase III trial. The Phase III ALINA study compared Alecensa to platinum-based chemotherapy. Results from the trial “provide evidence for the first time that this medicine could also play a pivotal role in early-stage disease where there is significant u
PharmaVoice
SEPTEMBER 1, 2023
The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.
Nixon Gwilt Law
SEPTEMBER 1, 2023
The buzz around ChatGPT, steady for the last year, continues to build. With OpenAI’s upcoming launch of ChatGPT Enterprise, digital health leaders should pay close attention to the opportunities this groundbreaking technology could unlock for their organizations. So what exactly is ChatGPT Enterprise and why does it matter? Let’s explore how this powerful large language model (LLM) could transform digital health solutions when tailored to industry-specific use cases.
Pharmaceutical Technology
SEPTEMBER 1, 2023
Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmacy Times
SEPTEMBER 1, 2023
In a previous trial, DARE-19, investigators reported that the SGLT2 inhibitor dapagliflozin did not benefit patients with COVID-19 who had cardiometabolic risk factors.
Pharmaceutical Technology
SEPTEMBER 1, 2023
Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.
Pharmaceutical Commerce
SEPTEMBER 1, 2023
Session offers information on industry readiness, plus an overview of a phase implementation recommendation.
Pharmaceutical Technology
SEPTEMBER 1, 2023
Twist and Ono will discover and develop novel antibodies to treat autoimmune diseases and generate comprehensive discovery campaigns.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmacy Times
SEPTEMBER 1, 2023
Although the pandemic has negatively influenced the care that patients with cardiovascular conditions receive, the study authors found that there were not significant inequities regarding patients’ race.
Pharmaceutical Technology
SEPTEMBER 1, 2023
NexImmune will reduce its workforce from 47 to just 22 full-time employees and has also paused enrolment for three of its trials.
PharmExec
SEPTEMBER 1, 2023
Shift comes with $5 million dedication to launch Cencora’s healthier futures grant program.
Pharmaceutical Technology
SEPTEMBER 1, 2023
When expectant mothers are diagnosed with gestational diabetes mellitus (GDM) they often feel anxious and need extra support.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Progressive Medical
SEPTEMBER 1, 2023
You must be a registered user to view this information. The post Monthly Employee Portal Updates | August 2023 appeared first on Progressive Medical, Inc.
Pharmaceutical Technology
SEPTEMBER 1, 2023
The company announced a strategic shake-up that includes layoffs, leadership changes and halting of early-stage programs.
Pharmacy Times
SEPTEMBER 1, 2023
Heart health may influence long-term brain health as early as middle age.
Pharmaceutical Technology
SEPTEMBER 1, 2023
Huadong has entered into an agreement to acquire licence rights for MC2 Therapeutics’ Wynzora cream in Greater China.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
299 
Let's personalize your content